Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Abstract of this article
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hadziyannis, S. J.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

SUMMARIES FOR PATIENTS

Duration and Dose of Antiviral Treatment for Chronic Hepatitis C

2 March 2004 | Volume 140 Issue 5 | Page I-67

Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.

Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.

The summary below is from the full report titled "Peginterferon-{alpha}2a and Ribavirin Combination Therapy in Chronic Hepatitis C. A Randomized Study of Treatment Duration and Ribavirin Dose." It is in the 2 March 2004 issue of Annals of Internal Medicine (volume 140, pages 346-355). The authors are S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P.J. Pockros, A. Lin, and A.M. Ackrill, for the PEGASYS International Study Group.


What is the problem and what is known about it so far?
space

Hepatitis C is inflammation of the liver caused by hepatitis C virus (HCV). Hepatitis C virus has at least 6 distinct genetic makeups (genotypes). The type is important because it affects the way that the virus reacts to drug treatments. Genotype 1 is the most common and the most resistant. Hepatitis C virus is transmitted primarily by blood-to-blood contact; sexual transmission appears to be uncommon. Risk factors include body piercing, intravenous drug use, needlestick accidents, and blood transfusions (before hepatitis screening in 1992). Most people cannot get rid of HCV on their own. More than 80% keep the virus in their blood for longer than 6 months and get chronic hepatitis C.

Chronic hepatitis C progresses slowly over 10 to 30 years. It causes inflammation and scarring of the liver and, if untreated, can lead to liver failure and liver cancer. Treatment clears HCV from the blood and prevents further liver damage. Doctors treat chronic hepatitis C with powerful antiviral drugs that have many side effects. Recently, they found that combining a long-acting immunity-boosting protein (pegylated interferon) with another antiviral drug (ribavirin) was very effective in ridding the body of HCV. However, they did not determine the optimal duration or dose of this therapy.


Why did the researchers do this particular study?
space

To compare short- with long-term pegylated interferon therapy combined with either low or standard doses of ribavirin in patients with chronic hepatitis C.


Who was studied?
space

1311 patients with chronic hepatitis C from 99 international centers.


How was the study done?
space

Researchers randomly assigned patients to 1 of 4 groups. The groups received either pegylated interferon-{alpha}2a for 6 months or 1 year plus either low-dose (800 mg) or standard-dose (1000 to 1200 mg) ribavirin. Pegylated interferon-{alpha}2a was injected under the skin weekly. Ribavirin tablets were taken by mouth daily. The researchers and the patients did not know who got which dose of ribavirin. The researchers measured levels of HCV in the blood regularly during treatment and at 3 to 6 months after treatment. They routinely did blood tests, physical examinations, and interviews to check for side effects. They then assessed which treatment regimen got rid of the virus most often (undetectable levels of HCV at the end of treatment and during follow-up) and whether HCV genotype affected treatment response.


What did the researchers find?
space

In patients with HCV genotype 1, long-term treatment for 1 year with pegylated interferon-{alpha}2a plus standard doses of ribavirin more often rid the body of HCV than did short-term treatment or low-dose ribavirin. Longer treatment duration and higher ribavirin dose were not necessary to rid the body of virus in patients with genotypes 2 or 3. Severe side effects and stopping treatment early were more common with patients receiving 1-year treatment than in those receiving 6-month treatment.


What were the limitations of the study?
space

Study participants had abnormal liver enzyme levels and no other serious illnesses. We do not know whether patients with normal liver enzyme levels or other coexisting conditions, such as HIV infection, will respond similarly.


What are the implications of the study?
space

Patients with chronic hepatitis and HCV genotype 1 require higher ribavirin doses and longer-term combination treatment than do those with genotypes 2 or 3.


Related articles in Annals:

Reviews
Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?
Stefan Zeuzem
Annals 2004 140: 370-381. [ABSTRACT][Full Text]  

Summaries for Patients
Duration and Dose of Antiviral Treatment for Chronic Hepatitis C
Annals 2004 140: I-67. [Full Text]  



This article has been cited by other articles:


Home page
 Schizophr BullHome page
M. Huckans, A. Mitchell, S. Ruimy, J. Loftis, and P. Hauser
Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia
Schizophr Bull, June 17, 2008; (2008) sbn065v1.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Sarasin-Filipowicz, E. J. Oakeley, F. H. T. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M. H. Heim
Interferon signaling and treatment outcome in chronic hepatitis C
PNAS, May 13, 2008; 105(19): 7034 - 7039.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. D. Woodhouse, C. Smith, M. Michelet, N. Branza-Nichita, M. Hussey, R. A. Dwek, and N. Zitzmann
Iminosugars in Combination with Interferon and Ribavirin Permanently Eradicate Noncytopathic Bovine Viral Diarrhea Virus from Persistently Infected Cells
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1820 - 1828.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Aguilar Marucco, D. Gonzalez de Requena, S. Bonora, C. Tettoni, M. Bonasso, T. De Blasi, A. D'Avolio, M. Sciandra, M. Siccardi, L. Baietto, et al.
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon
J. Antimicrob. Chemother., April 1, 2008; 61(4): 919 - 924.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
B. R. Schackman, P. A. Teixeira, G. Weitzman, A. I. Mushlin, and I. M. Jacobson
Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree?
Med Decis Making, April 1, 2008; 28(2): 233 - 242.
[Abstract] [PDF]

Home page
 GutHome page
T Asselah, I Bieche, S Narguet, A Sabbagh, I Laurendeau, M-P Ripault, N Boyer, M Martinot-Peignoux, D Valla, M Vidaud, et al.
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
Gut, April 1, 2008; 57(4): 516 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
T J S Cross, C G Antoniades, and P M Harrison
Current and future management of chronic hepatitis C infection
Postgrad. Med. J., April 1, 2008; 84(990): 172 - 176.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. T. Shi, K. J. Herlihy, J. P. Graham, S. A. Fuhrman, C. Doan, H. Parge, M. Hickey, J. Gao, X. Yu, F. Chau, et al.
In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase
Antimicrob. Agents Chemother., February 1, 2008; 52(2): 675 - 683.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. A. Pineda, J. A. Mira, I. d. l. S. Gil, B. Valera-Bestard, A. Rivero, D. Merino, J. A. Giron-Gonzalez, M. J. Rios-Villegas, M. Gonzalez-Serrano, A. Collado, et al.
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1347 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Ma, W.-R. Jiang, N. Robledo, V. Leveque, S. Ali, T. Lara-Jaime, M. Masjedizadeh, D. B. Smith, N. Cammack, K. Klumpp, et al.
Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species
J. Biol. Chem., October 12, 2007; 282(41): 29812 - 29820.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
E. Tuaillon, A.-M. Mondain, L. Ottomani, L. Roudiere, P. Perney, M.-C. Picot, F. Seguret, F. Blanc, D. Larrey, P. Van de Perre, et al.
Impact of Hepatitis C Virus (HCV) Genotypes on Quantification of HCV RNA in Serum by COBAS AmpliPrep/COBAS TaqMan HCV Test, Abbott Antiretroviral Therapy HCV RealTime Assay, and VERSANT HCV RNA Assay
J. Clin. Microbiol., September 1, 2007; 45(9): 3077 - 3081.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
J. R. Ticehurst, F. M. Hamzeh, and D. L. Thomas
Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis
J. Clin. Microbiol., August 1, 2007; 45(8): 2426 - 2433.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. Lindh, E. Alestig, B. Arnholm, A. Eilard, K. Hellstrand, M. Lagging, T. Wahlberg, R. Wejstal, J. Westin, and G. Norkrans
Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection
J. Clin. Microbiol., August 1, 2007; 45(8): 2439 - 2445.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. J. Donlin, N. A. Cannon, E. Yao, J. Li, A. Wahed, M. W. Taylor, S. H. Belle, A. M. Di Bisceglie, R. Aurora, J. E. Tavis, et al.
Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy
J. Virol., August 1, 2007; 81(15): 8211 - 8224.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Chevaliez, R. Brillet, E. Lazaro, C. Hezode, and J.-M. Pawlotsky
Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection
J. Virol., July 15, 2007; 81(14): 7732 - 7741.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. L. Shiffman, F. Suter, B. R. Bacon, D. Nelson, H. Harley, R. Sola, S. D. Shafran, K. Barange, A. Lin, A. Soman, et al.
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
N. Engl. J. Med., July 12, 2007; 357(2): 124 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Yano, M. Ikeda, K.-i. Abe, H. Dansako, S. Ohkoshi, Y. Aoyagi, and N. Kato
Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2016 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. K. Gupta, E. Sellers, E. Somoza, L. Angles, K. Kolz, and D. L. Cutler
The Effect of Multiple Doses of Peginterferon alfa-2b on the Steady-State Pharmacokinetics of Methadone in Patients With Chronic Hepatitis C Undergoing Methadone Maintenance Therapy
J. Clin. Pharmacol., May 1, 2007; 47(5): 604 - 612.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. J. Koziel and M. G. Peters
Viral Hepatitis in HIV Infection
N. Engl. J. Med., April 5, 2007; 356(14): 1445 - 1454.
[Full Text] [PDF]

Home page
 J. Virol.Home page
M. W. Taylor, T. Tsukahara, L. Brodsky, J. Schaley, C. Sanda, M. J. Stephens, J. N. McClintick, H. J. Edenberg, L. Li, J. E. Tavis, et al.
Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy
J. Virol., April 1, 2007; 81(7): 3391 - 3401.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M.-L. Yu, C.-Y. Dai, J.-F. Huang, N.-J. Hou, L.-P. Lee, M.-Y. Hsieh, C.-F. Chiu, Z.-Y. Lin, S.-C. Chen, M.-Y. Hsieh, et al.
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
Gut, April 1, 2007; 56(4): 553 - 559.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A. A Butt, A. C Justice, M. Skanderson, M. O Rigsby, C. B Good, and C K. Kwoh
Rate and predictors of treatment prescription for hepatitis C
Gut, March 1, 2007; 56(3): 385 - 389.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. D. Scott and D. R. Gretch
Molecular Diagnostics of Hepatitis C Virus Infection: A Systematic Review
JAMA, February 21, 2007; 297(7): 724 - 732.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. E D. Santos, N. Partovi, J.-A. E Ford, and E. M Yoshida
Use of Hematopoietic Growth Factors as Adjuvant Therapy for Anemia and Neutropenia in the Treatment of Hepatitis C
Ann. Pharmacother., February 1, 2007; 41(2): 268 - 275.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
K. Agarwal, T. J S Cross, and C. Gore
Chronic hepatitis C
BMJ, January 13, 2007; 334(7584): 54 - 55.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. Wohnsland, W. P. Hofmann, and C. Sarrazin
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
Clin. Microbiol. Rev., January 1, 2007; 20(1): 23 - 38.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Liu, K. Abid, J. Pichardo, V. Pazienza, P. Ingravallo, R. Kong, S. Agrawal, S. Bogen, A. Saksena, K.-C. Cheng, et al.
In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease
J. Antimicrob. Chemother., January 1, 2007; 59(1): 51 - 58.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. H. Hoofnagle and L. B. Seeff
Peginterferon and Ribavirin for Chronic Hepatitis C
N. Engl. J. Med., December 7, 2006; 355(23): 2444 - 2451.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Dutartre, C. Bussetta, J. Boretto, and B. Canard
General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues
Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4161 - 4169.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M Sherman, E M Yoshida, M Deschenes, M Krajden, V G Bain, K Peltekian, F Anderson, K Kaita, S Simonyi, R Balshaw, et al.
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
Gut, November 1, 2006; 55(11): 1631 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
Y. Horsmans
Interferon-induced depression in chronic hepatitis C
J. Antimicrob. Chemother., October 1, 2006; 58(4): 711 - 713.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. A. Jones, L. E. Clancy, W. D. Rawlinson, and P. A. White
High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3019 - 3027.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M P Manns, H Wedemeyer, and M Cornberg
Treating viral hepatitis C: efficacy, side effects, and complications.
Gut, September 1, 2006; 55(9): 1350 - 1359.
[Full Text] [PDF]

Home page
 J. Virol.Home page
K.-S. Chang, Z. Cai, C. Zhang, G. C. Sen, B. R. G. Williams, and G. Luo
Replication of Hepatitis C Virus (HCV) RNA in Mouse Embryonic Fibroblasts: Protein Kinase R (PKR)-Dependent and PKR-Independent Mechanisms for Controlling HCV RNA Replication and Mediating Interferon Activities.
J. Virol., August 1, 2006; 80(15): 7364 - 7374.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
S. S. Lee and T. Wong
Hepatitis C: reviewing the options.
Can. Med. Assoc. J., July 4, 2006; 175(1): 64 - 64.
[Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
P. Halfon, M. Bourliere, G. Penaranda, H. Khiri, and D. Ouzan
Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection.
J. Clin. Microbiol., July 1, 2006; 44(7): 2507 - 2511.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
K. Patel, A. J Muir, and J. G McHutchison
Diagnosis and treatment of chronic hepatitis C infection.
BMJ, April 29, 2006; 332(7548): 1013 - 1017.
[Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
M. A. Rifai, J. K. Moles, and D. D. Short
Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness
Psychiatr Serv, April 1, 2006; 57(4): 570 - 572.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. B. Perni, S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, et al.
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
Antimicrob. Agents Chemother., March 1, 2006; 50(3): 899 - 909.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
C. Sarrazin, B. C. Gartner, D. Sizmann, R. Babiel, U. Mihm, W. P. Hofmann, M. von Wagner, and S. Zeuzem
Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5.
J. Clin. Microbiol., March 1, 2006; 44(3): 729 - 737.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
M. A. Rifai, J. K. Moles, L. P. Lehman, and B. J. Van der Linden
Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders.
Psychosomatics, March 1, 2006; 47(2): 112 - 121.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M Diago, G Castellano, J Garcia-Samaniego, C Perez, I Fernandez, M Romero, O L Iacono, and C Garcia-Monzon
Association of pretreatment serum interferon {gamma} inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
Gut, March 1, 2006; 55(3): 374 - 379.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. A Hughes and S. D Shafran
Treatment of Hepatitis C in HIV-Coinfected Patients
Ann. Pharmacother., March 1, 2006; 40(3): 479 - 489.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
T. Wong and S. S. Lee
Hepatitis C: a review for primary care physicians
Can. Med. Assoc. J., February 28, 2006; 174(5): 649 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
K. McNelis
Management of Hepatitis C Infection in the HIV-Infected Patient
Journal of Pharmacy Practice, February 1, 2006; 19(1): 37 - 52.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. A Hughes and S. D Shafran
Chronic Hepatitis C Virus Management: 2000-2005 Update
Ann. Pharmacother., January 1, 2006; 40(1): 74 - 82.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Brau
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy
J. Antimicrob. Chemother., December 1, 2005; 56(6): 991 - 995.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
S. Hazari, A. Patil, V. Joshi, D. E. Sullivan, C. D. Fermin, R. F. Garry, R. M. Elliott, and S. Dash
Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes
J. Gen. Virol., November 1, 2005; 86(11): 3047 - 3053.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. Brok, L. L. Gluud, and C. Gluud
Effects of Adding Ribavirin to Interferon to Treat Chronic Hepatitis C Infection: A Systematic Review and Meta-analysis of Randomized Trials
Arch Intern Med, October 24, 2005; 165(19): 2206 - 2212.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Rodriguez-Torres, F. J. Torriani, V. Soriano, M. J. Borucki, E. Lissen, M. Sulkowski, D. Dieterich, K. Wang, J.-M. Gries, P. G. Hoggard, et al.
Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 3997 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
K. Naka, K. Takemoto, K.-i. Abe, H. Dansako, M. Ikeda, K. Shimotohno, and N. Kato
Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type I interferon receptors
J. Gen. Virol., October 1, 2005; 86(10): 2787 - 2792.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
E. Rodriguez-Inigo, J. M. Lopez-Alcorocho, J. Bartolome, N. Ortiz-Movilla, M. Pardo, and V. Carreno
Percentage of Hepatitis C Virus-Infected Hepatocytes Is a Better Predictor of Response Than Serum Viremia Levels
J. Mol. Diagn., October 1, 2005; 7(4): 535 - 543.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Mangia, R. Santoro, N. Minerva, G. L. Ricci, V. Carretta, M. Persico, F. Vinelli, G. Scotto, D. Bacca, M. Annese, et al.
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
N. Engl. J. Med., June 23, 2005; 352(25): 2609 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S M Kamal, A A El Tawil, T Nakano, Q He, J Rasenack, S A Hakam, W A Saleh, A Ismail, A A Aziz, and M A. Madwar
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response
Gut, June 1, 2005; 54(6): 858 - 866.
[Abstract] [Full Text] [PDF]